🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 21 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/04/2019 10,91 11,43 10,42 10,49 -3,58% 9,26% 105.800
26/04/2019 10,74 10,97 10,64 10,88 +1,78% 3,04% 53.200
25/04/2019 10,76 10,78 10,41 10,69 -0,83% 3,44% 46.400
24/04/2019 11,08 11,08 10,54 10,78 -2,00% 4,87% 42.700
23/04/2019 10,97 11,16 10,77 11,00 +0,92% 3,56% 62.100
22/04/2019 11,17 11,33 10,76 10,90 -2,94% 5,10% 46.600
18/04/2019 10,88 11,35 10,35 11,23 +3,03% 9,19% 68.100
17/04/2019 12,25 12,25 10,75 10,90 -10,87% 12,24% 130.900
16/04/2019 12,63 12,75 12,19 12,23 -2,32% 4,43% 41.400
15/04/2019 12,81 13,12 12,06 12,52 -2,34% 8,27% 37.700
12/04/2019 13,14 13,44 12,76 12,82 -1,69% 5,18% 40.300
11/04/2019 13,40 13,66 12,89 13,04 -2,54% 5,78% 62.600
10/04/2019 12,69 13,41 12,69 13,38 +5,94% 5,67% 65.300
09/04/2019 12,74 13,00 12,60 12,63 -1,41% 3,14% 46.000
08/04/2019 12,49 13,07 12,28 12,81 +2,40% 6,33% 71.500
05/04/2019 12,09 12,58 11,92 12,51 +3,65% 5,46% 143.800
04/04/2019 11,99 12,27 11,89 12,07 +0,84% 3,17% 37.200
03/04/2019 11,91 12,10 11,81 11,97 +1,44% 2,43% 46.700
02/04/2019 11,76 12,00 11,55 11,80 -0,76% 3,83% 82.800
01/04/2019 12,61 12,68 11,81 11,89 -4,80% 6,90% 102.300
29/03/2019 11,98 12,65 11,84 12,49 +4,96% 6,76% 194.600
28/03/2019 11,45 11,98 11,39 11,90 +4,02% 5,15% 37.900
27/03/2019 11,54 11,62 11,12 11,44 -0,87% 4,38% 53.000
26/03/2019 11,40 11,84 11,21 11,54 +2,76% 5,53% 84.300
25/03/2019 11,19 11,48 11,02 11,23 +0,36% 4,11% 70.300
22/03/2019 11,70 11,89 10,99 11,19 -5,65% 7,69% 87.600
21/03/2019 11,48 12,00 11,41 11,86 +2,68% 5,14% 62.600
20/03/2019 11,58 12,18 11,25 11,55 -0,17% 8,03% 64.300
19/03/2019 11,91 12,09 11,42 11,57 -1,62% 5,62% 110.800
18/03/2019 12,04 12,60 11,76 11,76 +0,77% 6,98% 166.600